Analysis of 13F filings for the 03/31/2025 reporting period indicates that institutional investors collectively increased their aggregate holdings in AbbVie Inc (ABBV). Between December 31, 2024, and March 31, 2025, funds added 5,236,474 shares, representing a 0.97% increase in their total reported positions. This broad accumulation suggests a generally positive sentiment towards the pharmaceutical company among a wide array of investment managers, as revealed by public disclosures.
Institutional investors collectively increased their aggregate long positions in AbbVie Inc. (ABBV) by 0.97%, adding 5,236,474 shares to reach 546,652,055 shares between December 31, 2024, and March 31, 2025. This broad accumulation across 4,507 funds suggests a mildly positive sentiment and sustained institutional interest in the pharmaceutical giant. Vanguard Group Inc. (173.9M shares) and BlackRock Inc. (145.9M shares) remain the top institutional holders. While the overall trend was positive, a specific batch of 33 recent 13F filers showed a net reduction of 89,555 shares, yet a net increase in market value of $14.235 million. This indicates significant price appreciation for ABBV during the period, offsetting share reductions by some funds within this subset. This divergence underscores the importance of analyzing aggregate data over individual fund movements. It is crucial to note that 13F filings only disclose long equity positions, offering an incomplete view of a fund's overall strategy, as short positions or other derivatives are not reported. Therefore, while the aggregate increase in long holdings suggests positive sentiment, it does not account for potential bearish bets or hedging activities. Investors should consider this inherent limitation when interpreting institutional positioning data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
